Accelerate Diagnostics, Inc. (AXDX) Files An 8-K Regulation FD Disclosure

Accelerate Diagnostics, Inc. (AXDX) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01

Regulation FD Disclosure.

On November 9, 2016, Accelerate Diagnostics, Inc. (the Company)
hosted a conference call to discuss its results of operations for
the quarter ended September 30, 2016. A copy of the transcript of
the conference call is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 for Form 8-K, the
information in this Form 8-K, including Exhibit 99.1, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is filed as an exhibit to
this Current Report on Form 8-K:
Exhibit
Number Description
99.1

Earnings Call Transcript, November 9, 2016


About Accelerate Diagnostics, Inc. (AXDX)


An ad to help with our costs